Compare KRRO & ONL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRRO | ONL |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.0M | 165.4M |
| IPO Year | 2019 | 2021 |
| Metric | KRRO | ONL |
|---|---|---|
| Price | $12.94 | $2.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 2 |
| Target Price | ★ $34.80 | $3.00 |
| AVG Volume (30 Days) | 293.6K | ★ 618.5K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.83% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $6,392,000.00 | ★ $147,647,000.00 |
| Revenue This Year | N/A | $4.10 |
| Revenue Next Year | N/A | $3.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 181.46 | N/A |
| 52 Week Low | $5.20 | $1.92 |
| 52 Week High | $55.89 | $3.04 |
| Indicator | KRRO | ONL |
|---|---|---|
| Relative Strength Index (RSI) | 49.17 | 35.98 |
| Support Level | $10.32 | $2.62 |
| Resistance Level | $14.78 | $2.66 |
| Average True Range (ATR) | 1.18 | 0.10 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 28.77 | 9.09 |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Orion Properties Inc is an internally managed real estate investment trust engaged in the ownership, acquisition, and management of a diversified portfolio of office properties located in high-quality suburban markets across the United States and leased mainly on a single-tenant net lease basis to creditworthy tenants. Its portfolio is comprised of traditional office properties, as well as governmental, medical office, flex/laboratory, and R&D and flex/industrial properties. The company is focused on shifting its portfolio concentration over time away from traditional office properties, towards more dedicated use assets with specialized uses that include an office component. It operates in one business segment: commercial real estate.